Opko Health Inc (OPK)

[WiseFool]

Pfizer’s Mikael Dolsten "Opko’s product, which is the next generation of products in the field."

One Of Pfizer’s Cooperative Ventures ‘Opko Health’

How do the products of Protalix Biotherapeutics Inc. (NYSE MKT:PLX; TASE: PLX) and Opko Health Inc. (NYSE: OPK; TASE: OPK) fit in with this business?

Pfizer’s Mikael Dolsten: President, Worldwide Research & Development and Executive Vice President of Pfizer Inc.

“We realize that Israel has vast experience in the biological realm. According to our definition, Opko and Protalix are in the rare diseases field. Opko works with human growth hormone, in which we have a great deal of experience, mainly with children. It enables us to greatly improve the existing product using technology that makes it possible to administer human growth hormone more frequently. Protalix’s product for Gaucher’s Disease is a smaller product for us. It enters the market almost like biological generics (in contrast to Opko’s product, which is the next generation of products in the field). Its sales are therefore relatively low, compared with what certain people may have expected. But we’re satisfied with all of our products that help patients.”

Full Article